Aravive Inc (ARAV)
ARAV
Oncology
BiotechSign Signal Grade
F
Signal Grade
3.8/100 composite signal score
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Insider Buying
0
Publications
100
Clinical Activity
4
Pipeline Overview
- Therapeutic Focus
- Oncologysrc
Clinical Trial Activity
1
Clinical Trial
(ClinicalTrials.gov aggregate)
(ClinicalTrials.gov aggregate)
1 Phase 1
Trial Phase Breakdown
5
PubMed Publications
0
Catalyst Records
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Recent News & SEC Filings
- SEC 8-K 8-K - Current report
- SEC 8-K 8-K - Current report
- SEC 8-K 8-K - Current report
- SEC 8-K 8-K - Current report
- SEC 8-K 8-K - Current report
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
- Real-World Efficacy and Safety of Belzutifan in Sporadic Metastatic Renal Cell Carcinoma. — Clin Genitourin Cancer 2026 Oct PMID 42692967
- Comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in patients with newly diagnosed homologous recombination-deficient stage III/IV ovarian cancer: Findings from cohort C of the OPAL phase 2 trial. — Gynecol Oncol 2026 Sep PMID 42623963
- Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients With Renal Cell Carcinoma With Bone Metastases: RADICAL (Alliance A031801). — J Clin Oncol 2026 Aug 20 PMID 42507969
- Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive HER2-negative breast cancer: safety and patient-reported outcomes from the phase III TROPION-Breast01 study. — ESMO Open 2026 Aug PMID 42497483
- Poly(adenosine diphosphate-ribose) polymerase inhibitor maintenance therapy with niraparib in patients with primary advanced or recurrent endometrial cancer receiving dostarlimab plus chemotherapy. — Int J Gynecol Cancer 2026 Aug PMID 42391799
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Aravive Inc.
Full ARAV Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.